The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Keytruda (pembrolizumab) on April 19, 2019. This approval was based on demonstrated efficacy, as indicated by the supplemental application BLA 125514 S-54.
Background
Keytruda (pembrolizumab) is a prescription medicine that has received prior FDA approvals. This supplemental application pertains to its efficacy, indicating a review of additional data supporting its therapeutic benefits.
What this means
A supplemental approval for efficacy indicates that the FDA has reviewed and accepted new data supporting the therapeutic benefits of Keytruda. While the specific details of the new indication, patient population, or treatment context are not provided in the source information, such approvals are crucial for expanding the utility of established medications. They allow for updates to the drug's official prescribing information, providing healthcare professionals with new guidelines on its appropriate use. This process ensures that the drug's label accurately reflects the most current scientific evidence regarding its effectiveness, potentially offering new treatment options or refining existing ones for patients.
Source
The information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA) website. The approval for supplemental application BLA 125514 S-54 was dated April 19, 2019, and is available on accessdata.fda.gov.